$2.38
-0.02[-0.83%]
At close: Apr 18
$2.38
0[0.00%]
PreMarket: 8:26AM EDT
Innate Pharma
(NASDAQ:IPHA)Innate Pharma Stock (NASDAQ:IPHA), Analyst Ratings, Price Targets, Predictions
Innate Pharma SA has a consensus price target of $10.83, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 11, 2024, March 22, 2024, and November 15, 2023. With an average price target of $11.5 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 383.19% upside for Innate Pharma SA from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
SVB Leerink
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Innate Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 03/24/2023 | IPHA | Buy Now | Innate Pharma | $2.38 | 383.19% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11.5 | Reiterates | → Buy | Get Alert |
| 11/15/2022 | IPHA | Buy Now | Innate Pharma | $2.38 | 278.15% | SVB Leerink | Daina Graybosch | $10 → $9 | Maintains | Outperform | Get Alert |
| 09/16/2022 | IPHA | Buy Now | Innate Pharma | $2.38 | 404.2% | Citigroup | Yigal Nochomovitz | $16 → $12 | Maintains | Buy | Get Alert |
| 08/02/2022 | IPHA | Buy Now | Innate Pharma | $2.38 | 320.17% | SVB Leerink | Daina Graybosch | $11 → $10 | Maintains | Outperform | Get Alert |
| 05/11/2022 | IPHA | Buy Now | Innate Pharma | $2.38 | 362.18% | SVB Leerink | Daina Graybosch | $10 → $11 | Maintains | Outperform | Get Alert |
| 09/17/2021 | IPHA | Buy Now | Innate Pharma | $2.38 | 278.15% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
| 09/03/2021 | IPHA | Buy Now | Innate Pharma | $2.38 | — | SVB Leerink | Daina Graybosch | — | Upgrade | Market Perform → Outperform | Get Alert |
| 09/02/2021 | IPHA | Buy Now | Innate Pharma | $2.38 | — | SVB Leerink | Daina Graybosch | — | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for Innate Pharma (IPHA)?
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on April 11, 2024. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 383.19% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Innate Pharma (IPHA)?
The latest analyst rating for Innate Pharma (NASDAQ: IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.
When was the last upgrade for Innate Pharma (IPHA)?
The last upgrade for Innate Pharma SA happened on September 3, 2021 when SVB Leerink raised their price target to N/A. SVB Leerink previously had a market perform for Innate Pharma SA.
When was the last downgrade for Innate Pharma (IPHA)?
There is no last downgrade for Innate Pharma.
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Innate Pharma (IPHA) correct?
While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $0.00 to $11.50. The current price Innate Pharma (IPHA) is trading at is $2.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.